Expertise in
37
conditions

Dr. Fadi S. Braiteh

Oncology
Comprehensive Cancer Center Of Nevada
3730 S Eastern Ave, 
Las Vegas, NV 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
37
conditions
Comprehensive Cancer Center Of Nevada
3730 S Eastern Ave, 
Las Vegas, NV 

Overview

Fadi Braiteh is an Oncologist practicing medicine in Las Vegas, Nevada.

Dr. Braiteh is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Agranulocytosis, Familial Colorectal Cancer, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 36 clinical trials. Dr. Braiteh is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

Sunrise Hospital And Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
SelectHealth
  • HMO
  • POS
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Comprehensive Cancer Center of Nevada
3730 S Eastern Ave, Las Vegas, NV 89169

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

31 Clinical Trials

A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drug: SGN-B6A
Study Phase: Phase 1
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Terminated
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: July 06, 2026
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Drug
Study Drugs: BT8009, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
View 9 Less Clinical Trials

53 Total Publications

Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
Journal: ESMO open
Published: October 03, 2025
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

Comprehensive Cancer Centers Of Nevada

3730 S Eastern Ave, 
Las Vegas, NV 
 (0.1 miles away)
702-952-3400
Languages Spoken:
English
See accepted insurances

Nicholas Vogelzang is an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Vogelzang is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Orchiectomy, and Nephrectomy.

Expertise in
61
conditions
Expertise in
61
conditions
Referral may be required

Comprehensive Cancer Centers Of Nevada

7445 Peak Dr, 
Las Vegas, NV 
 (9.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anu Thummala is an Oncologist practicing medicine in Las Vegas, Nevada. Dr. Thummala is highly rated in 61 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Thummala is currently accepting new patients.

Expertise in
50
conditions
Expertise in
50
conditions
Referral required
Before you request

Comprehensive Cancer Centers Of Nevada

3730 S Eastern Ave, 
Las Vegas, NV 
 (0.1 miles away)
702-952-3400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Telehealth Visits are Available Edwin Kingsley, MD is a medical oncologist at Comprehensive Cancer Centers of Nevada (CCCN). He is board certified in internal medicine and medical oncology. Dr. Kingsley is an adjunct clinical professor at Touro University and has been teaching medical students for more than 14 years.My approach to patient care is to consider the entire patient, and not just his or her disease. I try to understand everything about the patient, their social, cultural, education, and family history, in addition to their medical history, and the disease for which they have been referred to me for treatment. This global approach to the patient gives me the proper and total context to help me deliver the very best care I can. Dr. Kingsley is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, and Lung Cancer. Dr. Kingsley is board certified in Internal Medicine (Sub: Medical Oncology) and Internal Medicine. Dr. Kingsley is currently accepting new patients.

Frequently Asked Questions about Dr. Fadi S. Braiteh

Is Dr. Fadi S. Braiteh a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Fadi S. Braiteh is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Fadi S. Braiteh specialize in?

While Dr. Fadi S. Braiteh is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Fadi S. Braiteh participate in research or clinical trials?

Yes. Dr. Fadi S. Braiteh has published 53 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Fadi S. Braiteh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Fadi S. Braiteh accept my insurance?

Dr. Fadi S. Braiteh accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Braiteh's expertise for a condition
ConditionClose
    View All 14 Distinguished Conditions
    View All 23 Advanced Conditions
    View All 101 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile